RT Journal Article
SR Electronic
T1 High-Throughput Clinical Trial Emulation with Real World Data and Machine Learning: A Case Study of Drug Repurposing for Alzheimer’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.31.22270132
DO 10.1101/2022.01.31.22270132
A1 Zang, Chengxi
A1 Zhang, Hao
A1 Xu, Jie
A1 Zhang, Hansi
A1 Fouladvand, Sajjad
A1 Havaldar, Shreyas
A1 Cheng, Feixiong
A1 Chen, Kun
A1 Chen, Yong
A1 Glicksberg, Benjamin S.
A1 Chen, Jin
A1 Bian, Jiang
A1 Wang, Fei
YR 2022
UL http://medrxiv.org/content/early/2022/03/10/2022.01.31.22270132.abstract
AB Clinical trial emulation, which is the process of mimicking targeted randomized controlled trials (RCT) with real-world data (RWD), has attracted growing attention and interest in recent years from the pharmaceutical industry. Different from RCTs which have stringent eligibility criteria for recruiting participants, RWD are more representative of real-world patients to whom the drugs will be prescribed. One technical challenge for trial emulation is how to conduct effective confounding control with complex RWD so that the treatment effects can be objectively derived. Recently many approaches, including deep learning algorithms, have been proposed for this goal, but there is still no systematic evaluation and practical guidance on them. In this paper, we emulate 430, 000 trials from two large-scale RWD warehouses, covering both electronic health records (EHR) and general claims, over 170 million patients spanning more than 10 years, aiming to identify new indications of approved drugs for Alzheimer’s disease (AD). We have investigated the behaviors of multiple different approaches including logistic regression and deep learning models, and propose a new model selection strategy that can significantly improve the performance of confounding balance of the participants in different arms of emulated trials. We demonstrate that regularized logistic regression-based propensity score (PS) model outperforms the deep learning-based PS model and others, which contradicts with our intuitions to a certain extent. Finally, we identified 8 drugs whose original indications are not AD (pantoprazole, gabapentin, acetaminophen, atorvastatin, albuterol, fluticasone, amoxicillin, and omeprazole), hold great potential of being beneficial to AD patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work of C.Z., H.Z. and F.W. were supported by NIH awards R01MH124740 and RF1AG072449, as well as NSF award 1750326. B.S.G. is supported by NIH grant RF1AG059319. J.B. is supported by NIH awards R21AG068717, R56AG069880, R01CA246418-02S1, and R21CA245858-01A1S1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Weill Cornell Medicine with protocol number 21-07023759. The use of OneFlorida data for this study is approved under the University of Florida IRB number IRB202001888. Access to the MarketScan data analyzed in this manuscript is provided by the University of Kentucky.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOneFlorida data can be requested through https://onefloridaconsortium.org/front-door/. Since OneFlorida data is a HIPAA-limited data set, a data use agreement needs to be established with the OneFlorida network.The MarketScan dataset is available from IBM at https://www.ibm.com/products/marketscan-research-databases. https://onefloridaconsortium.org/front-door/